Shares of Aquestive Therapeutics surged +11.1% to $4.20 after the FDA accepted the company's resubmitted application for its under-the-tongue epinephrine film — a drug that, if approved, would become the first needle-free rescue treatment for life-threatening allergic reactions. The agency assigned a review deadline of March 16, 2027, classifying the resubmission as a Class 2 response — a standard six-month review rather than the faster three-month track the company had hoped for.

  • The January Rejection Was About Packaging, Not the Drug Itself. The original rejection letter raised no concerns about the drug's chemistry, manufacturing, or clinical results comparing it to auto-injectors like EpiPen . The FDA only asked for a human factors study on packaging and a confirmatory blood-level study, which could run simultaneously . The redesigned packaging cut the time to open from 17 seconds to 3 seconds , directly addressing the regulator's concern. That narrow scope makes a second rejection less likely — though never impossible.

  • The Market Opportunity Is Large, but the Stock Has Already Priced In Hope. Epinephrine auto-injector prescriptions grew at a 15% annual rate from 2021–2023, and the company estimates the U.S. market could roughly double from ~$850 million in 2025 to ~$2 billion by 2031 . Management has called the drug a "billion-dollar commercial opportunity" globally . Yet shares trade around a ~$500 million market cap — meaning investors are pricing in meaningful but far from certain success.

  • Cash Is the Looming Constraint. Aquestive ended Q2 2026 with $98.5 million in cash, down from $121 million at year-end . Analysts have flagged that this may not be enough to fund a full commercial launch without tapping $75 million from RTW and $20 million from Oaktree, both contingent on FDA approval . The company plans a 75-person sales team targeting 8,000 prescribers — a lean operation, but one that still requires capital it doesn't yet have in hand.

  • International Filings Add a Second Catalyst. A Canadian drug submission is planned for Q4 2026 , and European filings are in progress. These ex-U.S. milestones could unlock licensing deals that both validate the drug and inject non-dilutive cash before the March verdict.

The stock's rebound reverses a week-long slide but leaves shares well below their 2025 highs. Until March 16, AQST is a binary bet: approval unlocks a first-of-its-kind product in a growing market; a second rejection would severely test the balance sheet.